Login
Navigate Fool.com
Will ICLR beat
the market?

ICON plc (ADR)

NASDAQ: ICLR

Community Rating: 4 Stars: Favorite

43.64 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $43.93
Previous Close $43.64
Daily Range $43.07 - $44.83
52-Week Range $29.07 - $50.00
Market Cap $2.7B
P/E Ratio 26.61
Dividend (Yield) $0.00 (0.0%)
Volume 198,633
Average Daily Volume 421,401
Current FY EPS $2.17

How do you think ICLR
will perform against the market?

Top ICLR Bull/Bear Pitches

 

dollarpimp (< 20)
Submitted January 19, 2008

Discounted earnings valuation assuming 25% earnings growth over 10 years indicates this stock is selling at a substantial discount. Even assuming 20%, it's fairly priced. Just backed off a new high, … More

0 Replies Reply Report this Post
 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

4 Disruptive Stocks Biotechs Depend On

Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.

S&P 500 chips away at major resistance

Worried About Obamacare? Invest in This Sector Instead

Looking for health-care exposure in your portfolio, but want to steer clear of the Obamacare debate? Then this little-known health-care industry could be the answer.

Why Selling CROs Like Parexel May Be Short-Sighted

Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.

ICON Reports second quarter 2013 Revenue of $334 million, up 21% year on year, non-GAAP EPS of 43c a

ICON shareholders vote in favour of all resolutions at its Annual General Meeting

ICON Reports First Quarter 2013 Revenue of $317 Million, up 26% year on year and non-GAAP EPS of 36c

ICON Wins ‘Partnership Pioneers of the Year’ Award in Recognition of Global Partnership with Pfizer

ICON Public Beats on Both Top and Bottom Lines

Just the facts, Fool.

Long-Term Deals With Drug Makers Help Icon's Earnings

See More ICLR News...

Sector

Healthcare

Industry

Healthcare Information Services

ICON plc (ADR) (ICLR) Description

The Company is a contract research organization, providing clinical research and development services on a global basis to the pharmaceutical, biotechnology and medical device industries. Website: http://www.iconplc.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks